PLoS ONE (Jan 2019)

Optoacoustic properties of Doxorubicin - A pilot study.

  • Melanie A Kimm,
  • Claudia Gross,
  • Xose Luis Déan-Ben,
  • Avihai Ron,
  • Ernst J Rummeny,
  • Hsiao-Chun Amy Lin,
  • Carsten Höltke,
  • Daniel Razansky,
  • Moritz Wildgruber

DOI
https://doi.org/10.1371/journal.pone.0217576
Journal volume & issue
Vol. 14, no. 5
p. e0217576

Abstract

Read online

Doxorubicin (DOX) is a widely used chemotherapeutic anticancer drug. Its intrinsic fluorescence properties enable investigation of tumor response, drug distribution and metabolism. First phantom studies in vitro showed optoacoustic property of DOX. We therefore aimed to further investigate the optoacoustic properties of DOX in biological tissue in order to explore its potential as theranostic agent. We analysed doxorubicin hydrochloride (Dox·HCl) and liposomal encapsulated doxorubicin hydrochloride (Dox·Lipo), two common drugs for anti-cancer treatment in clinical medicine. Optoacoustic measurements revealed a strong signal of both doxorubicin substrates at 488 nm excitation wavelength. Post mortem analysis of intra-tumoral injections of DOX revealed a detectable optoacoustic signal even at three days after the injection. We thereby demonstrate the general feasibility of doxorubicin detection in biological tissue by means of optoacoustic tomography, which could be applied for high resolution imaging at mesoscopic depths dictated by effective penetration of visible light into the biological tissues.